Despite the fact that a company spokesman has denied the rumors, TanabeSeiyaku of Japan reached a nine-year high last week following a report in the country's International Pharmaceutical Intelligence journal which claimed that the drugmaker is finalizing either a merger or acquisition. However, Bloomberg News cites analysts as saying that this is an oft-repeated rumor that makes no sense at the present time, as Tanabe is about to launch a series of new drugs and make appointments to its management team.
Tanabe recently revised its consolidated sales forecast for the fiscal year ended March 3 to 193 billion yen ($1.59 billion), an increase of 2.7%, as a result of solid domestic growth of drugs such as Ceredist (taltireline) for the treatment of spinocerebellar degeneration, and down payments received from licensing deals for the firm's antidiabetic and anti-inflammatory agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze